Antibody engineering is rarely a straightforward journey; it can be viewed as a cyclical process of understanding, design, production, and observation. These stages form the foundation of an informed engineering process, accelerating the development of antibodies for diverse applications.
Gaining a deeper understanding of the starting material, including complete antibody sequences, binding kinetics, binding epitopes and 3D conformations offers essential details to fuel the engineering process.
An informed engineering process requires in-depth characterization on the performance of the resulting engineered antibody. Does the antibody bind to the intended epitope? What are the binding kinetics of the antibody? Was there a change in the glycan profile? How well was it produced? Addressing these questions ensures the effectiveness of engineered antibodies, enhancing their utility in therapeutic and diagnostic applications.
De novo antibody sequencing, epitope mapping with HDX-MS and kinetic analysis with SPR, and glycan analysis can answer these questions to better inform your antibody engineering process.